In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after
allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator …

Context.—A complete diagnosis of acute leukemia requires knowledge of clinical
information combined with morphologic evaluation, immunophenotyping and karyotype …

Mutations of the NPM1 gene (NPM1 mut) are among the most common genetic alterations in
acute myeloid leukemia and are suitable for minimal residual disease detection. We …

Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor
outcomes and relapse risk prediction approaches have not changed significantly in …

Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1)
pre‐allogeneic hematopoietic cell transplantation (HCT) may have measurable residual …

Proteins created from recurrent fusion genes like CBFB-MYH11 are prevalent in acute
myeloid leukemia (AML), often necessary for leukemogenesis, persistent throughout the …

In this study, we evaluated the impact of secondary genetic lesions in acute myeloid
leukemia (AML) with inv (16)(p13. 1q22) or t (16; 16)(p13. 1; q22); CBFB-MYH11. We …

Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …

Identifying mechanisms underlying relapse is a major clinical issue for effective cancer
treatment. The emerging understanding of the importance of metastasis in hematologic …

Therapeutic resistance remains the principal problem in acute myeloid leukemia (AML). We
used area under receiver-operating characteristic curves (AUCs) to quantify our ability to …